New drug combo for brain lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of three drugs (rituximab, methotrexate, and orelabrutinib) plus a PD-1 inhibitor for newly diagnosed or relapsed central nervous system lymphoma. The goal is to see if this new combination can improve outcomes for patients with this rare type of lymphoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a new diagnosis of primary central nervous system lymphoma (PCNSL) or secondary central nervous system lymphoma (SCNSL) that has come back after treatment.
- You must be 18 years or older and able to give written consent.
- A recent brain MRI shows at least one measurable tumor.
- You have adequate organ function (blood counts, liver, kidneys, heart, and thyroid).
- You have not had previous treatment with certain immunotherapies (like PD-1 inhibitors or CAR-T cells).
- You do not have active serious infections, autoimmune diseases, or other cancers that are not controlled.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (teniposide, a PD-1 checkpoint inhibitor, and selinexor) for people with relapsed or refractory primary central nervous system lymphoma. It aims to see if this three-drug approach can shrink tumors or slow the disease when previous treatments haven't worked.
This trial tests a combination of three drugs — high-dose methotrexate, thiotepa, and zanubrutinib — for people newly diagnosed with primary central nervous system lymphoma (PCNSL). The goal is to see if this combination is safe and effective in shrinking tumors and improving outcomes.
This trial tests a combination of two drugs, epcoritamab and ibrutinib, for people whose lymphoma has come back or not responded to treatment and has spread to the brain or spinal cord. The goal is to see if this combination can help control the disease.
This trial tests three drugs together—pomalidomide, an anti-PD-1 antibody, and selinexor—to treat primary central nervous system lymphoma (a blood cancer in the brain) that has returned after previous treatment. The goal is to see if this combination can shrink the cancer and help patients live longer.
This trial tests a combination of chemotherapy drugs to treat lymphoma that started in your brain. The goal is to see if this treatment helps without having to use whole-brain radiation.
This trial tests whether adding an immunotherapy drug to standard chemotherapy helps people with newly diagnosed primary central nervous system lymphoma (a rare brain cancer) live longer without the disease getting worse. It compares the combination to chemotherapy alone.
Hear when a new Primary Central Nervous System Lymphoma (PCNSL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.